Effectiveness of ultra-long-term lithium treatment: relevant factors and case series.
Bipolar disorder
Lithium
Ultra-long-term prophylaxis
Journal
International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
20
11
2023
accepted:
18
02
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
The phenomenon of preventing the recurrences of mood disorders by the long-term lithium administration was discovered sixty years ago. Such a property of lithium has been unequivocally confirmed in subsequent years, and the procedure makes nowadays the gold standard for the pharmacological prophylaxis of bipolar disorder (BD). The efficacy of lithium prophylaxis surpasses other mood stabilizers, and the drug has the longest record as far as the duration of its administration is concerned. The continuation of lithium administration in case of good response could be a lifetime and last for several decades. The stability of lithium prophylactic efficacy in most patients is pretty steady. However, resuming lithium after its discontinuation may, in some patients, be less efficient. In the article, the clinical and biological factors connected with the prophylactic efficacy of long-term lithium administration are listed. Next, the adverse and beneficial side effects of such longitudinal treatment are presented. The main problems of long-term lithium therapy, which could make an obstacle to lithium continuation, are connected with lithium's adverse effects on the kidney and, to lesser extent, on thyroid and parathyroid functions. In the paper, the management of these adversities is proposed. Finally, the case reports of three patients who have completed 50 years of lithium therapy are described. The authors of the paper reckon that in the case of good response, lithium can be given indefinitely. Given the appropriate candidates for such therapy and successful management of the adverse effects, ultra-long term lithium therapy is possible and beneficial for such patients.
Sections du résumé
BACKGROUND
BACKGROUND
The phenomenon of preventing the recurrences of mood disorders by the long-term lithium administration was discovered sixty years ago. Such a property of lithium has been unequivocally confirmed in subsequent years, and the procedure makes nowadays the gold standard for the pharmacological prophylaxis of bipolar disorder (BD). The efficacy of lithium prophylaxis surpasses other mood stabilizers, and the drug has the longest record as far as the duration of its administration is concerned. The continuation of lithium administration in case of good response could be a lifetime and last for several decades. The stability of lithium prophylactic efficacy in most patients is pretty steady. However, resuming lithium after its discontinuation may, in some patients, be less efficient.
MAIN BODY
METHODS
In the article, the clinical and biological factors connected with the prophylactic efficacy of long-term lithium administration are listed. Next, the adverse and beneficial side effects of such longitudinal treatment are presented. The main problems of long-term lithium therapy, which could make an obstacle to lithium continuation, are connected with lithium's adverse effects on the kidney and, to lesser extent, on thyroid and parathyroid functions. In the paper, the management of these adversities is proposed. Finally, the case reports of three patients who have completed 50 years of lithium therapy are described.
CONCLUSIONS
CONCLUSIONS
The authors of the paper reckon that in the case of good response, lithium can be given indefinitely. Given the appropriate candidates for such therapy and successful management of the adverse effects, ultra-long term lithium therapy is possible and beneficial for such patients.
Identifiants
pubmed: 38489135
doi: 10.1186/s40345-024-00328-9
pii: 10.1186/s40345-024-00328-9
pmc: PMC10942952
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7Informations de copyright
© 2024. The Author(s).
Références
Br J Psychiatry. 2022 Jul;221(1):425-427
pubmed: 35318909
Pharmaceuticals (Basel). 2023 Jan 03;16(1):
pubmed: 36678571
Am J Psychiatry. 2004 Feb;161(2):217-22
pubmed: 14754766
Neuropsychopharmacology. 2019 Feb;44(3):620-628
pubmed: 30487653
Am J Geriatr Psychiatry. 2017 Apr;25(4):357-362
pubmed: 28161155
Br J Psychiatry. 2023 Oct;223(4):456-464
pubmed: 37395140
Bipolar Disord. 2019 Aug;21(5):394-409
pubmed: 31112628
Br J Psychiatry. 2022 Sep;221(3):567-576
pubmed: 35184778
Mol Psychiatry. 2018 Jun;23(6):1453-1465
pubmed: 28242870
Neurosci Biobehav Rev. 2022 Mar;134:104266
pubmed: 34265322
Lancet. 2010 Jan 30;375(9712):385-95
pubmed: 20092882
Bipolar Disord. 2015 Jun;17(4):375-80
pubmed: 25359625
Psychiatry Res. 1991 Mar;36(3):329-31
pubmed: 1905823
Med Sci Monit. 2012 Nov;18(11):CR656-60
pubmed: 23111741
Lancet. 2012 Feb 25;379(9817):721-8
pubmed: 22265699
Bipolar Disord. 2018 Mar;20(2):97-170
pubmed: 29536616
Nature. 2015 Nov 5;527(7576):95-9
pubmed: 26524527
Mol Psychiatry. 2021 Jun;26(6):2457-2470
pubmed: 32203155
Adv Biochem Psychopharmacol. 1995;49:127-47
pubmed: 7653332
Ann Endocrinol (Paris). 2022 Aug;83(4):219-225
pubmed: 35074396
Med J Aust. 1949 Sep 3;2(10):349-52
pubmed: 18142718
Transplantation. 2014 Feb 15;97(3):e23-4
pubmed: 24492429
Eur Neuropsychopharmacol. 2022 Jan;54:100-115
pubmed: 34980362
Transl Psychiatry. 2018 Sep 5;8(1):183
pubmed: 30185780
Neuropsychobiology. 2000;42 Suppl 1:2-10
pubmed: 11093063
Complex Psychiatry. 2021 Dec;7(3-4):80-89
pubmed: 36408127
Neuropsychobiology. 2010;62(1):27-35
pubmed: 20453532
Br J Psychiatry. 2022 Aug;221(2):494
pubmed: 35505515
Neuropsychobiology. 2010;62(1):72-8
pubmed: 20453537
BMJ. 2013 Jun 27;346:f3646
pubmed: 23814104
Int J Bipolar Disord. 2013 Jul 31;1:11
pubmed: 25505678
J Clin Psychiatry. 2008 Dec;69(12):1860-8
pubmed: 19026269
Bipolar Disord. 2005 Oct;7(5):404-17
pubmed: 16176433
J Trauma Dissociation. 2016 Jul-Sep;17(4):397-409
pubmed: 26683845
Acta Psychiatr Scand. 2019 Aug;140(2):94-115
pubmed: 31218667
Brain Sci. 2023 Apr 29;13(5):
pubmed: 37239213
Eur Neuropsychopharmacol. 2020 May;34:19-27
pubmed: 32305265
Acta Psychiatr Scand. 2020 Feb;141(2):131-141
pubmed: 31667829
Int J Bipolar Disord. 2015 Dec;3(1):32
pubmed: 26183461
Pharmacopsychiatry. 2019 Sep;52(5):232-236
pubmed: 30731477
Bipolar Disord. 2014 Mar;16(2):151-8
pubmed: 24636202
Acta Psychiatr Scand. 2017 Apr;135(4):319-327
pubmed: 27987204
BMC Nephrol. 2018 Nov 3;19(1):305
pubmed: 30390660
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4770-5
pubmed: 11287659
Bipolar Disord. 2020 May;22(3):255-265
pubmed: 31466131
Acta Psychiatr Scand. 1996 Nov;94(5):344-7
pubmed: 9124081
Int J Neuropsychopharmacol. 2010 Jun;13(5):617-22
pubmed: 20392298
Am J Psychiatry. 2005 Jul;162(7):1281-90
pubmed: 15994710
Compr Psychiatry. 1964 Dec;5(6):396-408
pubmed: 14238742
Sci Rep. 2021 Sep 8;11(1):17823
pubmed: 34497278
Bipolar Disord. 2001 Apr;3(2):63-7
pubmed: 11333064
Transl Psychiatry. 2021 Nov 29;11(1):606
pubmed: 34845190
Mol Psychiatry. 2016 Sep;21(9):1290-7
pubmed: 26503763
Ment Health Clin. 2018 Mar 23;7(2):46-50
pubmed: 29955497
Bipolar Disord. 2006 Oct;8(5 Pt 2):625-39
pubmed: 17042835
J Affect Disord. 2013 Feb 20;145(2):187-9
pubmed: 22939170
PLoS One. 2013 Jun 19;8(6):e65636
pubmed: 23840348
Hum Psychopharmacol. 2019 Jul;34(4):e2708
pubmed: 31297898
Bipolar Disord. 2018 Feb 14;:
pubmed: 29441712
J Affect Disord. 2012 Sep;140(1):6-13
pubmed: 22154708
Lancet. 1968 May 4;1(7549):968-71
pubmed: 4171596
Int J Neuropsychopharmacol. 2009 May;12(4):447-58
pubmed: 18771602
Eur Neuropsychopharmacol. 2014 Apr;24(4):540-4
pubmed: 24503277
World J Biol Psychiatry. 2019 Jul;20(6):449-461
pubmed: 28854847
Lancet Psychiatry. 2015 Dec;2(12):1075-83
pubmed: 26453408
Mol Psychiatry. 2023 Jul 11;:
pubmed: 37433967
Fortschr Neurol Psychiatr. 1987 May;55(5):141-4
pubmed: 3110039
J Affect Disord. 2008 Sep;110(1-2):135-41
pubmed: 18329720
Pharmacogenomics J. 2016 Oct;16(5):446-53
pubmed: 27401222
Arch Gen Psychiatry. 1967 Feb;16(2):162-72
pubmed: 6019331
CNS Drugs. 2013 Mar;27(3):165-73
pubmed: 23378337
Ther Adv Psychopharmacol. 2016 Aug;6(4):277-82
pubmed: 27536347
Bipolar Disord. 2010 Feb;12(1):87-94
pubmed: 20148870
J Affect Disord. 2017 Aug 1;217:266-280
pubmed: 28437764
Front Psychiatry. 2018 May 31;9:207
pubmed: 29904359
Curr Alzheimer Res. 2016;13(8):873-8
pubmed: 26892288
Br J Hosp Med (Lond). 2020 Nov 2;81(11):1-9
pubmed: 33263481
Br J Psychiatry. 1963 Nov;109:803-9
pubmed: 14085007
Pharmacogenomics. 2015;16(14):1547-63
pubmed: 26343379
Genes Brain Behav. 2016 Sep;15(7):660-8
pubmed: 27324142
Sci Rep. 2020 Jul 22;10(1):12239
pubmed: 32699220
J Affect Disord. 1998 Jan;47(1-3):177-82
pubmed: 9476758
Int J Bipolar Disord. 2017 Dec;5(1):27
pubmed: 28480485
Psychiatry Res. 2017 Jan;247:305-309
pubmed: 27974284
J Clin Psychiatry. 2020 Aug 18;81(5):
pubmed: 32841553
Acta Psychiatr Scand. 1994 Oct;90(4):295-7
pubmed: 7832001
J Mol Neurosci. 2017 Aug;62(3-4):304-308
pubmed: 28616776
Pharmaceuticals (Basel). 2022 Jan 23;15(2):
pubmed: 35215246
Int J Bipolar Disord. 2023 Oct 15;11(1):34
pubmed: 37840048
Int J Bipolar Disord. 2014 Dec 20;2:15
pubmed: 25530932
Int J Bipolar Disord. 2023 Nov 16;11(1):35
pubmed: 37971552
Neuropsychobiology. 2010;62(1):8-16
pubmed: 20453530
Proc Natl Acad Sci U S A. 2017 May 30;114(22):E4462-E4471
pubmed: 28500272
Arch Gen Psychiatry. 2008 Nov;65(11):1331-5
pubmed: 18981345
Bipolar Disord. 2018 Dec;20(8):753-760
pubmed: 29578315
Int J Bipolar Disord. 2023 Apr 29;11(1):16
pubmed: 37119343
F1000Res. 2020 Feb 7;9:93
pubmed: 32518634
Braz J Psychiatry. 2021 Jul-Aug;43(4):407-413
pubmed: 32965432
Br J Psychiatry. 1963 Nov;109:810-4
pubmed: 14080575
Psychol Med. 2005 Dec;35(12):1685-94
pubmed: 16300686
Lancet. 2016 Mar 12;387(10023):1085-1093
pubmed: 26806518
Int J Bipolar Disord. 2020 May 20;8(1):21
pubmed: 32435920
J Clin Psychiatry. 2004 Mar;65(3):432-41
pubmed: 15096085